$ORKA insider trading
Over the last 12 months, Oruka Therapeutics insiders reported no purchases and 33 sales totaling $325.3M across SEC Form 4 filings. 67% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $325.3M 33 events
- Events · 12m
- 33 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 67% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Goncalves JoanaChief Medical Officer · O | ▼ Sale | 7,947 | $92.38 | $734K | -20% | plan · 5 tranches |
| Sep 15, 2026 | Agarwal ArjunSenior Vice President, Finance · O | ▼ Sale | 10,019 | $92.43 | $926K | -40.4% | plan · 5 tranches |
| Sep 15, 2026 | Klein Lawrence OttoChief Executive Officer · O·D | ▼ Sale | 2,452 | $95.71 | $235K | -0.3% | — |
| Sep 15, 2026 | Quinlan Paul TGeneral Counsel · O | ▼ Sale | 1,039 | $95.71 | $99K | -3.3% | — |
| Sep 15, 2026 | Sandler Laura LeeChief Operating Officer · O | ▼ Sale | 906 | $95.71 | $87K | -0.4% | — |
| Sep 1, 2026 | Sandler Laura LeeChief Operating Officer · O | ▼ Sale | 5,000 | $91.82 | $459K | -2.1% | plan · 2 tranches |
| Sep 1, 2026 | Klein Lawrence OttoChief Executive Officer · O·D | ▼ Sale | 75,000 | $91.83 | $6.9M | -7.5% | plan · 3 tranches |
| Aug 17, 2026 | Goncalves JoanaChief Medical Officer · O | ▼ Sale | 7,000 | $111.84 | $783K | -17.6% | plan · 4 tranches |
| Aug 14, 2026 | Quinlan Paul TGeneral Counsel · O | ▼ Sale | 52,000 | $108.49 | $5.6M | -62.6% | plan · 6 tranches |
| Aug 13, 2026 | Agarwal ArjunSenior Vice President, Finance · O | ▼ Sale | 10,000 | $106.66 | $1.1M | -39.5% | plan · 5 tranches |
| Jul 15, 2026 | Goncalves JoanaChief Medical Officer · O | ▼ Sale | 7,000 | $86.28 | $604K | -17.6% | plan · 4 tranches |
| Jul 13, 2026 | Agarwal ArjunSenior Vice President, Finance · O | ▼ Sale | 9,999 | $84.63 | $846K | -39.5% | plan · 4 tranches |
| Jul 1, 2026 | Fairmount Funds Management LLCD·10% | ▼ Sale | 3,553,410 | $84.43 | $300.0M | -75.8% | indirect |
| Jul 1, 2026 | Sandler Laura LeeChief Operating Officer · O | ▼ Sale | 5,000 | $94.42 | $472K | -2.1% | plan · 3 tranches |
| Jun 22, 2026 | Agarwal ArjunSenior Vice President, Finance · O | ▼ Sale | 1,587 | $80.95 | $128K | -9.4% | plan · 2 tranches |
| Jun 15, 2026 | Agarwal ArjunSenior Vice President, Finance · O | ▼ Sale | 9,854 | $69.72 | $687K | -36.8% | plan · 4 tranches |
| Jun 15, 2026 | Goncalves JoanaChief Medical Officer · O | ▼ Sale | 7,947 | $69.28 | $551K | -19.5% | plan · 4 tranches |
| Jun 15, 2026 | Klein Lawrence OttoChief Executive Officer · O·D | ▼ Sale | 1,729 | $69.69 | $120K | -0.2% | — |
| Jun 15, 2026 | Sandler Laura LeeChief Operating Officer · O | ▼ Sale | 600 | $69.69 | $42K | -0.3% | — |
| Jun 15, 2026 | Quinlan Paul TGeneral Counsel · O | ▼ Sale | 733 | $69.69 | $51K | -2.3% | — |
| Jun 12, 2026 | Dambkowski CarlD | ▼ Sale | 35,000 | $70.13 | $2.5M | -47.5% | plan · 2 tranches |
| May 1, 2026 | Sandler Laura LeeChief Operating Officer · O | ▼ Sale | 5,000 | $63.88 | $319K | -2.1% | plan · 6 tranches |
| Apr 15, 2026 | Goncalves JoanaChief Medical Officer · O | ▼ Sale | 7,000 | $66.12 | $463K | -17.3% | plan · 3 tranches |
| Mar 16, 2026 | Klein Lawrence OttoChief Executive Officer · O·D | ▼ Sale | 1,729 | $41.3 | $71K | -0.2% | — |
| Mar 16, 2026 | Agarwal ArjunSenior Vice President, Finance · O | ▼ Sale | 395 | $41.3 | $16K | -2.1% | — |
| Mar 16, 2026 | Sandler Laura LeeChief Operating Officer · O | ▼ Sale | 600 | $41.3 | $25K | -0.3% | — |
| Mar 16, 2026 | Goncalves JoanaChief Medical Officer · O | ▼ Sale | 7,641 | $40.91 | $313K | -18.6% | plan · 4 tranches |
| Mar 16, 2026 | Quinlan Paul TGeneral Counsel · O | ▼ Sale | 733 | $41.3 | $30K | -2.3% | — |
| Mar 2, 2026 | Sandler Laura LeeChief Operating Officer · O | ▼ Sale | 5,000 | $33.56 | $168K | -2.1% | plan · 2 tranches |
| Feb 17, 2026 | Goncalves JoanaChief Medical Officer · O | ▼ Sale | 7,000 | $32.37 | $227K | -17.1% | plan · 2 tranches |
| Jan 15, 2026 | Goncalves JoanaChief Medical Officer · O | ▼ Sale | 7,000 | $31.81 | $223K | -82.2% | plan · 2 tranches |
| Jan 2, 2026 | Sandler Laura LeeChief Operating Officer · O | ▼ Sale | 13,000 | $28.52 | $371K | -6% | plan · 3 tranches |
| Dec 19, 2025 | Goncalves JoanaChief Medical Officer · O | ▼ Sale | 7,000 | $30.61 | $214K | -82.2% | plan · 4 tranches |
Every $ORKA filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Oruka Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ORKA feed.